Dorthe Sandager Bilde

CMC Project Director at Symphogen

Dorthe Sandager Bilde has a diverse work experience spanning across multiple companies. Dorthe Sandager began their career as a QA Chemist at Novo Nordisk A/S in 2003, where they were responsible for the release of bulk products and handling of deviations and change requests. Dorthe Sandager then worked as a Research Scientist at LEO Pharma A/S from 2004 to 2006.

In 2006, Dorthe joined CMC Biologics A/S as a Scientist, focusing on the downstream development and purification of proteins and MAb's. Dorthe Sandager then became a Manager in 2008, where they managed the daily operations and development of the department. As a Principal Scientist from 2010 to 2013, they were responsible for process characterization and group coordination.

Following their tenure at CMC Biologics, Dorthe joined ALK Abelló in 2013 as a Project Chemist, where they worked until 2015.

Dorthe Sandager then joined Biogen in 2015, initially as a Program Manager in Tech transfer, and later as a Senior Associate II in Compliance, specifically in large-scale manufacturing.

In 2016, Dorthe joined Symphogen as a Senior Scientist and later transitioned to the role of CMC Project Director in 2017, where they currently work.

Dorthe Sandager Bilde's education history begins in 1992 when they attended Skanderborg Amtsgymnasium, although the degree and field of study for this period are not provided. From 1996 to 2002, they pursued a M.Sc in Chemical Engineering at DTU - Technical University of Denmark.

Location

Copenhagen, Denmark

Links

Previous companies


Org chart

This person is not in the org chart


Teams


Offices


Symphogen

3 followers

Symphogen is a clinical-stage antibody oncology focused company with a differentiated product pipeline and significant commercial opportunities. Inspired by nature, led by science and driven by people, we passionately strive to make that discovery that may have great effect on the lives of patients, their families, and their caregivers. Based on our monoclonal antibody (mAb) research platform, we create differentiated mAb and mAb mixture products candidates. Our pre-clinical and clinical pipeline is well suited for a precision-medicine approach by addressing well-defined, biomarker-selected patient populations. We are headquartered in Denmark with operations in the US.


Industries

Headquarters

Ballerup, Denmark

Employees

51-200

Links